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ABSTRACT 
Age-related macular degeneration (ARMD) is a major cause of central blindness among working aged adults across the 
world. Systematic research planning on any subject, including ARMD is in need of solid data regarding previous efforts in 
this field and to identify the gaps in the research. This study aimed to elucidate the most important trends, directions, 
and gap in this subject. 
The data extracted from the Institute for Scientific Information were used to perform a bibliometric analysis of the 
scientific productions (1993–2013) about ARMD. Specific parameters related to ARMD were analyzed to obtain a view of 
the topic’s structure, history, and document relationships. Additionally, the trends and authors in the most influential 
publications were analyzed.  
The number of articles in this field was found constantly increasing. Most highly cited articles addressed genetic 
epidemiology and clinical research topics in this field.  During the past 3 years, there has been a trend toward biomarker 
research.   
Through performing the first scientometric survey on ARMD research, we analyzed the characteristics of papers and the 
trends in scientific production.  We also identified some of the critical gaps in the current research efforts that would 
help in large-scale research strategic planning.  
KEY WORDS 
Age-related Macular Degeneration, Bibliometrics, Historiography, Scientometrics, Citation Analysis 
©2015, Med Hypothesis Discov Innov Ophthalmol. 
This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial 3.0 
License (CC BY-NC 3.0), which allows users to read, copy, distribute and make derivative works for non-commercial 
purposes from the material, as long as the author of the original work is cited properly. 
 
Correspondence to: 
Dr Shahrokh Ramin. Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Phone: +98 21 22591616, 
Fax: +98 21 22590607, Email: dr.ramin1346@gmail.com
 
INTRODUCTION 
Age-related macular degeneration (ARMD) is one of the 
top four causes of blindness in elderly people. ARMD, 
described more than 80 years ago, is a progressive 
disease of the central area in the ocular posterior 
segment (the macula lutea), which leads to a gradual 
deterioration in central vision and causes severe 
disability to affected individuals. In North America, 
Europe, and Australia, ARMD accounts for up to half of 
all cases of central blindness, affecting approximately 3% 
of the general adult population. In the United States, 
about 12%–15% of people older than 80 years of age 
were estimated to have ARMD in 2000, and this number 
is expected to be more than 2.95 million in 2020. People 
with ARMD have been found to experience reduced 
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quality of life, depression, and difficulty with the 
activities of daily living, which pose serious financial 
burden on their family in terms of high medical and 
societal costs that are due to increased risk of falling, 
need for vision enhancing equipment, 
depression/anxiety treatment, and assistance with 
activities of daily living (1, 2). 
Visual loss in late ARMD can be caused by either of the 
following two processes that cause photoreceptor 
dysfunction: geographic atrophy (GA) or choroidal 
neovascularization. GA refers to the confluent atrophy of 
the choriocapillaris and associated retinal pigment 
epithelium (RPE). The RPE is the outermost layer of the 
retina, which is involved in phagocytosis of the 
photoreceptor outer segments and biologic 
maintenance. In choroidal neovascularization, an 
ingrowth of new vessels occurs from the choriocapillaris 
invading the retina. These new vessels leak serous fluids 
beneath and into the neural retina causing fibrous 
scarring, which defines the late stage of ARMD 
(exudative, or neovascular) (3). Non-exudative (dry) 
ARMD is often marked by the formation of drusen, 
pigmentary changes in the RPE, and atrophy of the RPE. 
Dry ARMD is more common; in one series of autopsy 
eyes, ARMD was found in 33% of patients older than 65 
years (4, 5).  
The incidence of the disease increases with age. Through 
major breakthrough discoveries made in the last decade 
in treating the wet form of ARMD, the chance of 
stabilizing or increasing vision has been increased to 90%. 
Nonetheless, this improvement is associated with a 
significant price tag of monthly intravitreal injections 
(with the ever-present phantom of endophthalmitis and 
other injection-related adverse events) and uncertainty 
regarding the duration of treatment (6).  
A scientometrics method is one that measures and 
analyzes scientific publications related to a specific topic 
regarding the trends in citations, most important 
content, authors, and journals. A widespread use of 
scientometric method goes back to 1960s when Eugene 
Garfield finalized the construction of Science (7). In this 
article, we performed the first scientometric analysis of 
the ARMD field to elucidate the most important trends 
and directions of this subject. 
MATERIAL AND METHODS 
A bibliometric study was performed on the articles 
related to “Age-Related Macular Degeneration” 
published between 1993 and 2013. The Institute for 
Scientific Information (ISI) web of science available at 
http://www.isiknowledge.com was our main source. Two 
mesh terms—“Age-Related Macular Degeneration” and 
“ARMD”—already checked in Pubmed mesh database 
were used to conduct the search. 
Only original articles were selected for further 
evaluation. These articles were evaluated regarding 
citation characteristics, contributing role of each author, 
country, funding agency, institution, journal, and 
language of published articles. Articles were also 
evaluated regarding the trend of publication and citation 
during a selected time and also subject areas covered. 
Articles that were published in 10 countries with the 
greatest number of publications on the topic were 
analyzed separately. 
Articles published by each country were evaluated 
regarding subject areas and publishing journals. Special 
attention was paid to total citations with and without 
self-citation, citation per year, and citation per item for 
journals of each country. Articles that were cited more 
than 100 times were evaluated regarding year of 
publication, country of affiliation of the first author, and 
publishing journal. Number, country, and year of 
collaborative studies were also considered. All three 
resources available in the ISI web of science were used 
for this purpose (Science Citation Index Expanded, Social 
Sciences Citation Index, The Arts & Humanities Citation 
Index). For the citation analysis, two parameters were 
calculated: Local Citation Score (LCS) and Global Citation 
Score (GCS). LCS listed all papers sorted by citation 
frequency within the local (the starting bibliography) 
collection; however, GCS counted citations in the whole 
collection. For the citation burst analysis, first, 100 key 
words that generated the citation bursts were extracted, 
and then non-specific and general key words were 
omitted. 
RESULTS 
Annual Publication Number During 1993-2013 
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A total of 3235 research articles were available on ARMD 
in the ISI Web of Science during 1993-2013. These papers 
were drafted by 10,706 authors, 2332 institutions, and 
67 countries and were published in 388 journals in 9 
languages. Figure 1 demonstrates the growth rate of 
publications in this field (14.46% per year). The H-index 
of this subject was 125. 
 
Citation Profile of Articles  
The total LCS citations were 29,924 in number and GCS 
citations were 91,840 in number. The average citation 
per paper (C/P) was 28.39 
Table 1 shows the articles that were cited 100 or more 
times. Figure 2 shows the trend of citations during the 
period. Appendix 1 shows the highly cited articles in this 
field. Figure 1 shows the histogram map of 20 years of 
research in this field. 
Figure 3 shows the key words generating the highest 
citation bursts and the time periods associated with 
them. The key words associated with the highest citation 
bursts included: drusen, choroidal neovascular 
membranes, subfoveal neovascular membranes, 
neovascularization, subretinal neovascularization, 
blindness, fluorescein angiography, retinal pigment 
epithelium, choroidal perfusion abnormality, indocyanine 
green angiography, dystrophy, Beaver dam eye, Bruch 
membrane change, angiography, neovascular 
membranes, radiation therapy, photocoagulation, 
videoangiography, indocyanine green videoangiography, 
occult choroidal neovascularization, choriocapillaris, 
teletherapy, retinitis pigmentosa, Stargardt disease, 
mutations, apolipoprotein E, subfoveal choroidal 
neovascularization, laser photocoagulation, genome-
wide scan, susceptibility loci, verteporfin therapy, c-
reactive protein, avastin, pegaptanib, ranibizumab, 
polypoidal choroidal vasculopathy, complement factor H, 
bevacizumab, optical coherence tomography, 
polymorphism, endothelial growth factor, and vascular 
endothelial growth factor. 
Subject Analysis of the Most Highly Cited Documents  
The most common topics of the top 10 highly cited 
papers were genetic epidemiology research (40%), 
clinical study (surgical or pharmaceutical treatment) 
(50%), and epidemiologic study (10%) (Table 1). 
Languages, Journal Subjects, and Author Profiles of 
Publications  
Most ARMD articles were in English (3068), followed by 
German (105) and French (47). In total, the articles were 
written in nine languages (English, German, French, 
Portuguese, Hungarian, Spanish, Polish, Serbian, and 
Slovene). Dr R. Klein, with 80 articles, had the largest 
number of publications in the field of ARMD research 
(Table 2). When analyzed based on the number of papers 
in ARMD, 8 out of top 10 journals were general medical 
journals (such as the New England Journal of Medicine) 
and the remaining were ophthalmology journals. But 
when the same calculation was made based on the 
citation number (TLCS), seven journals were general 
medical journals and three were ophthalmology journals. 
When analyzed based on TGCS, highly cited papers were 
mostly published in general medical journals (80%), and 
the remaining 20% were published in Ophthalmology 
journals (Tables 3). No correlation was found between 
the impact factor of the most highly influential journals 
in this field and the total citations they had received for 
their papers in the field of ARMD. 
A majority of the top 10 universities and institutions in 
the list are from the United States and Australia. The first 
two of them are the Johns Hopkins University and 
University of Melbourne in terms of number of 
documents and Harvard University and University of 
Wisconsin in terms of number of citations (Table 4). 
Geographical Distribution  
In general, 67 countries contributed to the promotion of 
the field of ARMD by publishing articles. The United 
States, Germany, and the UK had the highest number of 
documents but they had the highest number of citations 
to their research papers in the field of ARMD (Table 5).  
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Table 1. Articles With Highest Number of Citations  
# Author/ Title / Journal  CITATION  
1 Klein Rj, Zeiss C, Chew Ey, Tsai Jy, Sackler Rs, Et Al. 
Complement Factor H Polymorphism In Age-Related Macular Degeneration 
Science. 2005 Apr 15; 308 (5720): 385-389 
 
 
 
1814 
2 Rosenfeld Pj, Brown Dm, Heier Js, Boyer Ds, Kaiser Pk, Et Al. 
Ranibizumab For Neovascular Age-Related Macular Degeneration 
New England Journal Of Medicine. 2006 Oct 5; 355 (14): 1419-1431 
 
 
 
1662 
3 Edwards Ao, Ritter R, Abel Kj, Manning A, Panhuysen C, Et Al. 
Complement Factor H Polymorphism And Age-Related Macular Degeneration 
Science. 2005 Apr 15; 308 (5720): 421-424 
 
 
 
1173 
4 Brown Dm, Kaiser Pk, Michels M, Soubrane G, Heier Js, Et Al. 
Ranibizumab Versus Verteporfin For Neovascular Age-Related Macular Degeneration 
New England Journal Of Medicine. 2006 Oct 5; 355 (14): 1432-1444 
 
 
 
1161 
5 Haines Jl, Hauser Ma, Schmidt S, Scott Wk, Olson Lm, Et Al. 
Complement Factor H Variant Increases The Risk Of Age-Related Macular Degeneration 
Science. 2005 Apr 15; 308 (5720): 419-421 
 
 
 
1148 
6 Gragoudas Es, Adamis Ap, Cunningham Et, Feinsod M, Guyer Dr 
Pegaptanib For Neovascular Age-Related Macular Degeneration 
New England Journal Of Medicine. 2004 Dec 30; 351 (27): 2805-2816 
 
 
 
1146 
7 Kassoff A, Kassoff J, Buehler J, Eglow M, Kaufman F, Et Al. 
A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C And E, Beta 
Carotene, And Zinc For Age-Related Macular Degeneration And Vision Loss - Areds Report No. 8 
Archives Of Ophthalmology. 2001 Oct; 119 (10): 1417-1436 
 1081 
8 Bressler Nm 
Photodynamic Therapy Of Subfoveal Choroidal Neovascularization In Age-Related Macular Degeneration 
With Verteporfin - One-Year Results Of 2 Randomized Clinical Trials - Tap Report 1 
Archives Of Ophthalmology. 1999 Oct; 117 (10): 1329-1345 
 
 
 
 
1021 
9 Friedman Ds, O'colmain B, Tomany Sc, Mccarty C, De Jong Ptvm, Et Al. 
Prevalence Of Age-Related Macular Degeneration In The United States 
Archives Of Ophthalmology. 2004 Apr; 122 (4): 564-572 
 
 
 
970 
10 Hageman Gs, Anderson Dh, Johnson Lv, Hancox Ls, Taiber Aj, Et Al. 
A Common Haplotype In The Complement Regulatory Gene Factor H (Hf1/Cfh) Predisposes Individuals To 
Age-Related Macular Degeneration 
Proceedings Of The National Academy Of Sciences Of The United States Of America. 2005 May 17; 102 (20): 
7227-7232 
 
 
 
929 
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Table 2. Most Active Authors in the Field of ARMD Research 
# Author Recs TLCS TGCS 
1 Klein R 80 2405 6370 
2 Bressler Nm 76 3639 10146 
3 Mitchell P 63 1300 3350 
4 Soubrane G 60 1202 3152 
5 Seddon Jm 58 2269 6377 
6 Schmidt-Erfurth U 56 1511 4504 
7 Holz Fg 55 550 2187 
8 Guymer Rh 52 310 855 
9 Wong Ty 52 422 1004 
10 Bressler Sb 48 2546 6735 
 
Figure 1. Annual Number of Published Papers 
 
The growth rate of 14.6% in the article numbers was observed. 
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Table 3. Journals with Highest Number of Papers in This Field 
# Journal Records Citation  2 year IF 5 year IF 
1 Ophthalmology 289 12624 5.563 5.777 
2 Investigative Ophthalmology & Visual Science 274 7421 3.441 3.730 
3 American Journal Of Ophthalmology 232 8043 3.631 4.292 
4 Retina-The Journal Of Retinal And Vitreous Diseases 225 3933 2.825 2.761 
5 British Journal Of Ophthalmology 198 4462 2.725 3.023 
6 Archives Of Ophthalmology 166 13369 3.826 4.160 
7 Graefes Archive For Clinical And Experimental Ophthalmology 125 2550 1.932 2.037 
8 Eye 97 1015 1.818 1.883 
9 Molecular Vision 73 1210 1.987 2.311 
10 Acta Ophthalmologica 65 408 2.345 2.428 
11 Ophthalmologica 57 503 1.412 1.236 
12 Klinische Monatsblatter Fur Augenheilkunde 49 197 0.699 0.473 
13 Ophthalmologe 48 295 0.529 0.681 
14 European Journal Of Ophthalmology 46 296 0.912 0.963 
15 Journal Francais D Ophtalmologie 45 112 0.438 0.443 
16 Japanese Journal Of Ophthalmology 43 234 1.274 1.488 
17 PLose One 43 493 3.730 4.244 
18 Ophthalmic Surgery Lasers & Imaging 39 634 1.464 0.922 
19 Canadian Journal Of Ophthalmology-Journal Canadien D Ophtalmologie 38 398 1.145 1.320 
20 Clinical And Experimental Ophthalmology 28 291 1.964 2.047 
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Table 4. Institutions with Highest Number of Papers 
# Institution Records Citations  
1 Johns Hopkins Univ 130 7472  
2 Univ Melbourne 125 3103  
3 Harvard Univ 117 9211  
4 Duke Univ 97 4450  
5 Univ Wisconsin 97 6462  
6 Nei 86 6282  
7 Univ Sydney 79 3584  
8 Moorfields Eye Hosp 73 2029  
9 Univ Penn 73 3241  
10 Univ Southern Calif 68 1737  
11 Univ Heidelberg 64 1960  
12 Univ Miami 57 5242  
13 UCL 54 1273  
14 Univ Paris 12 53 2140  
15 Natl Univ Singapore 51 809  
16 Univ Cologne 50 1054  
17 Univ Utah 49 2540  
19 Univ Iowa 48 3215  
20 Univ Bonn 47 1190 
 
DISCUSSION 
We analyzed the subject of highly cited papers, dividing 
them into two broad categories: epidemiology versus 
clinical research and translational versus basic science 
research (Appendix 1). Most of the highly cited papers 
were genetic epidemiology or clinical reports. Although 
ARMD is a debilitating disease and adversely affects the 
quality of life and emotional status of subjects, highly 
cited papers had largely neglected this subject. Highly 
cited reports also addressed the following subjects more 
frequently: (1) association of various genotypes with 
ARMD, (2) chemotherapy for wet ARMD, including the 
intravitreal treatment, and (3) effect of diet and vitamins 
on ARMD. Recently, as Appendix 2 shows, there has been 
a trend toward more applicable genetic epidemiology 
and translational research (biomarkers). In cluster 
analysis for the citations, we found the following three 
major clusters in the citation histogram map (Figure 1): 
(1) complement H factor polymorphism in the ARMD 
(nodes 831, 832, 833, and 842 in the index 1), (2) 
treatment of subfoveal choroidal neovascularization in 
ARMD (nodes 386, 402, and 428), and (3) ranibizumab 
treatment for neovascular ARMD (nodes 1116 and 1117).  
 
Table 5. Countries With Highest Number of Papers in the Field 
of ARMD 
# Country Recs CITATION  
1 USA 1338 60915  
2 Germany 363 8968  
3 UK 340 9990  
4 Australia 215 6031  
5 Japan 193 3740  
6 France 163 4862  
7 Peoples R China 144 2486  
8 Italy 120 1842  
9 Austria 112 3371  
10 Unknown 105 2707  
11 Canada 97 3205  
12 Switzerland 92 2959  
13 Netherlands 74 4699  
14 Spain 65 1184  
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Figure 2. Histogram Map of 20 Years of Research in ARMD 
 
 Proportionally, articles related to medical retina 
compared to other subspecialties have increased 
between 2005 and 2009. In an analytical study of the 
ophthalmology research papers, case–control or cohort 
studies comprised most study designs used (40.1%), 
followed by non-analytic studies (28.7%), basic science 
(24.6%), RCTs (3.3%), review articles (2.6%), and meta-
analyses (0.3%) (8). However, the trend was not similar in 
the ARMD research for the highly cited papers. As Graph 
3 shows, in the 1990s, the key words that resulted in the 
most strong citation bursts were the ones associated 
with pathophysiology, such as subretinal 
neovascularization; however, in the past 4 years, there 
has been a trend toward novel treatments such as 
ranibizumab in the context of RCTs, which shows the 
importance of this line of research and also the 
progression in the field of ARMD. Both the citation burst 
analysis and the histography of the most cited papers in 
the past 3 years showed that genetic epidemiology topics 
are among the recent hot topics in this field. 
Interestingly, genetic epidemiology studies also 
comprised the most highly cited articles in the past 20 
years, which implies that this field is still hot and many 
more studies have a high chance of publication in this 
field.In our study, the number of citations correlated 
poorly with the impact factor of the journals. Citation 
frequency and impact factor both render important 
information regarding the merit of a paper, but the 
ranking of research groups on the basis of journal impact 
factor is shown to have little correlation with the ranking 
of the same groups on the basis of citation frequency. 
This can be due to the fact that journals with an advance 
online publication had higher impact factors compared 
with those without an advance online publication. Also, 
researchers might prefer to publish their results in their 
subspecialty journal, which might not necessarily have a 
high impact factor. It is suggested that “citation analysis 
is a good rough indicator of the quality of work as it is 
perceived by other scientists” (9). Previously, two 
detailed citation analysis reports have been published, 
one spanning the period of 1850–1949 (10) and the other 
1975–2006 (11). In both reports, ARMD was a major 
citation classic, especially for ophthalmology journals. 
The second report surveyed 46 ophthalmology journals 
and concluded that the 100 most cited articles were 
published in 13 journals, including the Archives of 
Ophthalmology, Ophthalmology, and the American 
Journal of Ophthalmology (11). Epidemiology of ARMD 
was one of the major topics of 100 most cited articles. 
Also we found that the H-index of ARMD was 125, which 
indicates the appreciation of the context of ARMD within 
vision research. The publications of Dr Klein and several 
other top researchers in the field of ARMD research are 
also among the top 100 most cited articles in the field of 
Ophthalmology, which shows the importance of this 
field.
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Figure 3. Citation Burst Analysis 
Keywords  Strength  Begin  End  1992 - 2014  
Drusen  12.2823  1992  1998  ▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂  
Choroidal neovascular membranes  11.1771  1992  2002  ▃▃▃▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂  
Subfoveal neovascular membranes  4.9606  1992  2001  ▃▃▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂  
Neovascularization  4.4565  1992  2002  ▃▃▃▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂  
Subretinal neovascularization  4.4497  1992  2005  ▃▃▃▃▃▃▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂  
Blindness  4.2906  1992  2004  ▃▃▃▃▃▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂  
Fluorescein angiography  4.0001  1992  2000  ▃▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂  
Retinal-pigment epithelium  16.5474  1994  2002  ▂▂▃▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂  
Choroidal perfusion abnormality  3.746  1994  2002  ▂▂▃▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂  
Indocyanine green angiography  3.6439  1994  2003  ▂▂▃▃▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂  
Dystrophy  9.0779  1995  2002  ▂▂▂▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂  
Beaver dam eye  8.3643  1995  2001  ▂▂▂▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂  
Bruch membrane change  6.4945  1995  2004  ▂▂▂▃▃▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂  
Angiography  5.8675  1995  2000  ▂▂▂▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂  
Neovascular membranes  3.3267  1995  2000  ▂▂▂▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂  
Radiation-therapy  14.3348  1996  2001  ▂▂▂▂▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂  
Photocoagulation  9.7554  1996  2004  ▂▂▂▂▃▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂  
Videoangiography  9.2262  1996  2003  ▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂  
Indocyanine-green videoangiography  5.4875  1996  2002  ▂▂▂▂▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂  
Occult choroidal neovascularization  3.5868  1996  1997  ▂▂▂▂▃▃▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂  
Choriocapillaris  3.5137  1996  2003  ▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂  
Teletherapy  7.591  1997  2004  ▂▂▂▂▂▃▃▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂  
Retinitis-pigmentosa  9.5991  1998  2003  ▂▂▂▂▂▂▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂  
Stargardt-disease  8.4595  1999  2004  ▂▂▂▂▂▂▂▃▃▃▃▃▃▂▂▂▂▂▂▂▂▂▂  
Mutations  5.4898  1999  2002  ▂▂▂▂▂▂▂▃▃▃▃▂▂▂▂▂▂▂▂▂▂▂▂  
Apolipoprotein-e  4.587  2001  2005  ▂▂▂▂▂▂▂▂▂▃▃▃▃▃▂▂▂▂▂▂▂▂▂  
Subfoveal choroidal neovascularization  16.8328  2003  2006  ▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▂▂▂▂▂▂▂▂  
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Laser photocoagulation  13.8898  2003  2005  ▂▂▂▂▂▂▂▂▂▂▂▃▃▃▂▂▂▂▂▂▂▂▂  
Genomewide-scan  6.2849  2004  2006  ▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▂▂▂▂▂▂▂▂  
Susceptibility loci  8.7481  2005  2007  ▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▂▂▂▂▂▂▂  
Verteporfin therapy  13.1273  2006  2009  ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▂▂▂▂▂  
c-reactive protein  4.2676  2006  2008  ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▂▂▂▂▂▂  
Avastin  15.7886  2008  2010  ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▂▂▂▂  
Pegaptanib  5.9235  2008  2010  ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▂▂▂▂  
Ranibizumab  39.5427  2010  2014  ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃  
Polypoidal choroidal vasculopathy  7.0762  2010  2014  ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃▃  
Complement factor-h  5.5849  2010  2011  ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▂▂▂  
Bevacizumab  19.7189  2011  2014  ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃  
Optical coherence tomography  13.2565  2011  2014  ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃▃▃  
Polymorphism  3.7394  2012  2012  ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▂▂  
Endothelial growth-factor  3.5527  2012  2012  ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▂▂  
VEGF 5.228  2013  2014  ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▃▃  
 
Several lines of research have been previously identified as 
priorities in ARMD research. These include temporal patterns 
and changing the prevalence of ARMD; improvements of ocular 
imaging (eg, high-resolution OCT) to allow better phenotype 
classification of both early and late ARMD; and epidemiologic 
studies to determine gene-environment interactions for ARMD 
to identify early modifiable risk factors to prevent ARMD (12). 
According to the results of our study, several of these areas do 
not receive enough attention from the experts in the field, and 
better research strategies should be implemented. 
In conclusion, the result of our report as the first scientometric 
analysis of the research on ARMD can be used as a guideline for 
authors, researchers, and policy makers to determine the best 
ways to allocate their financial and workforce resources. 
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Appendix-1: Top most cited articles in the past 20 years. The numbers before the article indicate the location of the article on the histogram map. 
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